Business NewsPR NewsWire • Topiramate Exposure and Fetal Outcomes in Migraine Patients to Be Presented at the 136th ANA Annual Meeting

Topiramate Exposure and Fetal Outcomes in Migraine Patients to Be Presented at the 136th ANA Annual Meeting

Topiramate Exposure and Fetal Outcomes in Migraine Patients to Be Presented at the 136th ANA Annual Meeting

MOUNTAIN VIEW, Calif., Sept. 26, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that a poster authored by Dr. Mark W. Green, Director of the Center for Headache and Pain Medicine and Professor of Neurology and Anesthesiology at the Mount Sinai School of Medicine, will be...

View More : http://www.prnewswire.com/news-releases/topiramate-exposure-and-fetal-outcomes-in-migraine-patients-to-be-presented-at-t...
Releted News by prnewswire
Elsevier Launches European Journal of Cancer iPad Edition
Northern Oil & Gas, Inc. to Present at the IPAA Oil & Gas Investment Symposium in San Francisco
Topiramate Exposure and Fetal Outcomes in Migraine Patients to Be Presented at the 136th ANA Annual Meeting
Obama administration awards nearly $500 million in first round of grants to community colleges for job training and workforce development
Newly Released Mortgage Data Indicates Denial Rates for Minorities Improve